Altre lingue Cyclerion Therapeutics, Inc.

Azioni

CYCN

US23255M2044

Mercato chiuso - Nasdaq Altri mercati azionari 22:30:00 26/04/2024			Variaz. 5gg	Var. 1 gen.
2,93 ^USD	-3,62%		-16,29%	-12,54%

05/03	Cyclerion Therapeutics, Inc. riporta i risultati degli utili per l'intero anno terminato il 31 dicembre 2023	CI
2023	Cyclerion Therapeutics, Inc. nomina Regina Graul come Presidente	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Cyclerion Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	05/03
Cyclerion Appoints Regina Graul, Ph.D., as President	04/12
Cyclerion Therapeutics, Inc. Appoints Regina Graul as President	04/12
Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator	01/12
Cyclerion Therapeutics, Inc. Announces Board of Directors Appointments	01/12
Cyclerion Therapeutics, Inc. Announces Resignation of Ole Isacson as Director	24/11
Cyclerion Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
Cyclerion Therapeutics, Inc. Announces Anjeza Gjino Resigns as Chief Financial Officer	23/10/23
Cyclerion Therapeutics, Inc. - Tisento Launches with $81 Million from Top-Tier Investor Syndicate and Promising Cyclerion Assets	01/08/23
Cyclerion Therapeutics Acquires 10% Stake in Tisento Therapeutics in Asset Purchase Deal	31/07/23
Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets	31/07/23
Tisento Therapeutics, Inc. announced that it has received $81 million in funding from Cyclerion Therapeutics, Inc., Invus, Polaris, and other investors	31/07/23
Cyclerion Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	28/07/23
Cyclerion Therapeutics, Inc. Announces Resignation of Cheryl Gault as Chief Operating Officer	27/06/23
CYCLERION THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	01/06/23
Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement	01/06/23
Cyclerion Therapeutics : Private Placement - Form 8-K	25/05/23
CYCLERION THERAPEUTICS, INC. : Unregistered Sale of Equity Securities, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	25/05/23
Cyclerion Therapeutics, Inc. announced that it has received $5.000001 million in funding	25/05/23
Cyclerion Therapeutics to Implement 1-for-20 Reverse Stock Split	15/05/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Cyclerion Therapeutics, Inc.

Azioni

CYCN

US23255M2044

Altre lingue

Filtri